Promis Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based company, engaged in discovering and developing precision medicine solutions. The Company is focused on therapeutic antibodies and diagnostics for the diagnosis and treatment of misfolded protein diseases, including amyotrophic lateral sclerosis (ALS), cancer and Alzheimer's disease (AD). Its technology includes the Epitope Protection technology, ProMIS and AMFIA. Its technology targets misfolded superoxide dismutase 1 (SOD1) through a passive infusion of manufactured monoclonal antibodies and an active immunization approach to elicit the production of similar antibodies by the patient's own immune system. It is engaged in the development of a blood test that measures misfolded SOD1 in blood, for the diagnosis of ALS. It has developed a preclinical test for detection and measurement of aggregated Abeta, in animal models and a test for the detection of aggregated Abeta in human clinical samples.